Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride provides potassium ions essential for maintaining intracellular tonicity, transmembrane potential, and nerve impulse transmission. Dextrose 5% provides a source of calories and may improve serum osmolality. Sodium chloride 0.9% supplies sodium and chloride ions to maintain extracellular fluid volume and electrolyte balance.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Treatment of hypokalemia and prevention of potassium depletion,Maintenance of electrolyte balance in patients requiring intravenous fluids
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion: 10-20 m Eq/hour, not to exceed 40 m Eq/hour or 200 m Eq/day. Maximum concentration: 80 m Eq/L via peripheral line, 200 m Eq/L via central line. Rate dependent on serum potassium and clinical condition.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Not applicable as potassium is an endogenous electrolyte; distribution and elimination follow first-order kinetics with a rapid redistribution phase (t1/2 α ~15 min) and a slower terminal phase (t1/2 β ~6-8 h) reflecting equilibration with total body stores.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Potassium is primarily excreted unchanged by the kidneys; no significant hepatic metabolism. Dextrose is metabolized via glycolysis. Sodium and chloride are primarily renally excreted.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal (approximately 90% as potassium ion); minimal biliary/fecal elimination (<5% collectively).
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Minimal (approximately 0-5%); not bound to specific serum proteins, present as free ion.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Approximately 0.5–0.7 L/kg (total body water distribution); reflects equilibration with intracellular (98%) and extracellular (2%) compartments.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intravenous: 100% (complete bioavailability); oral (not applicable for this product): ~90% absorbed with first-pass effect.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
GFR >50 m L/min: no adjustment. GFR 10-50 m L/min: reduce dose by 25-50% or extend interval. GFR <10 m L/min: avoid use or use with extreme caution; reduce dose by 50-75% and monitor serum potassium closely.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
Child-Pugh A: no adjustment. Child-Pugh B: monitor potassium levels closely; no specific dose reduction required unless renal impairment present. Child-Pugh C: use with caution due to risk of hyperkalemia; individualize dosing based on serum potassium and renal function.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Intravenous infusion: 0.5-1 m Eq/kg/day for maintenance; for replacement, 0.3-0.5 m Eq/kg per hour with maximum rate 1 m Eq/kg/hour. Concentration not to exceed 40 m Eq/L peripherally. Dose based on serum potassium and clinical status.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Initiate at lower end of dosing range due to age-related decline in renal function. Maximum infusion rate: 10 m Eq/hour. Monitor renal function and serum potassium frequently. Avoid doses exceeding 100 m Eq per day unless severe hypokalemia.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Concentrated potassium chloride solutions (≥20 m Eq per 100 m L) must be diluted before administration to avoid fatal hyperkalemia. Administration must be via an infusion pump for rate control.
None.
Risk of hyperkalemia, especially in patients with renal impairment, adrenal insufficiency, or potassium-sparing diuretics,Monitor serum potassium and ECG during administration,Extravasation may cause tissue necrosis,Use with caution in patients with heart failure, edema, or conditions that cause sodium retention
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hyperkalemia,Acute or chronic renal failure (unless specific therapy is given),Addison's disease,Concurrent use of potassium-sparing diuretics,Severe metabolic alkalosis,In conditions with elevated potassium sensitivity (e.g., familial periodic paralysis)
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Avoid potassium-rich foods (bananas, oranges, potatoes, spinach, tomatoes, avocados) and salt substitutes containing potassium chloride to prevent hyperkalemia. Do not consume excessive amounts of high-potassium foods without medical guidance.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Potassium chloride is not associated with teratogenic risk in humans. There is no evidence of fetal harm from potassium administration at recommended doses. However, maternal hyperkalemia may cause fetal arrhythmia or adverse effects. Dextrose and sodium chloride are considered safe when used appropriately.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Potassium chloride is excreted into breast milk, but the amount is not clinically significant. The M/P ratio is not established. Dextrose and sodium chloride are normal components of breast milk. Use is considered compatible with breastfeeding.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Physiologic changes in pregnancy (increased plasma volume, glomerular filtration rate) may alter potassium requirements. Dose adjustments may be necessary to maintain normokalemia; monitoring of serum potassium is essential. Dextrose and sodium chloride doses should be adjusted based on fluid and glucose status.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Administer via slow IV infusion at a maximum rate of 10 m Eq/hour; use a central line for concentrations above 40 m Eq/L due to risk of phlebitis. Monitor serum potassium and ECG continuously during infusion. Contraindicated in severe renal impairment, hyperkalemia, or Addison's disease. Do not use as a bolus; risk of cardiac arrest.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This medication is given intravenously to correct low potassium levels.,Do not suddenly stop other potassium supplements unless directed by your doctor.,Report symptoms of hyperkalemia: muscle weakness, palpitations, tingling in hands/feet.,Avoid potassium-containing salt substitutes or excessive potassium-rich foods while on this therapy.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium chloride provides potassium ions essential for maintaining intracellular tonicity, transmembrane potential, and nerve impulse transmission. Dextrose 5% provides a source of calories and may improve serum osmolality. Sodium chloride 0.9% supplies sodium and chloride ions to maintain extracellular fluid volume and electrolyte balance.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Intravenous infusion: 10-20 m Eq/hour, not to exceed 40 m Eq/hour or 200 m Eq/day. Maximum concentration: 80 m Eq/L via peripheral line, 200 m Eq/L via central line. Rate dependent on serum potassium and clinical condition.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride is not associated with teratogenic risk in humans. There is no evidence of fetal harm from potassium administration at recommended doses. However, maternal hyper. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.